Meta-analysis of efficacy of Chinese medicine compound combined with concurrent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma

被引:0
|
作者
Cai, Yunxiang [1 ]
Zhong, Huaping [2 ]
Huang, Zhenhe [1 ,3 ]
机构
[1] Ganzhou Peoples Hosp, Dept Otolaryngol Head & Neck Surg, Ganzhou, Jiangxi, Peoples R China
[2] Gannan Med Coll, Affiliated Hosp 1, Dept Cardiovasc Med, Ganzhou, Jiangxi, Peoples R China
[3] Ganzhou Peoples Hosp, Dept Otolaryngol Head & Neck Surg, 16 Meiguan Ave, Ganzhou 341000, Jiangxi, Peoples R China
来源
关键词
Locally advanced nasopharyngeal carcinoma; radiotherapy; chemotherapy; Chinese medicine compound; meta-analysis; SHENQI FUZHENG INJECTION; SOPHORA-FLAVESCENS; GASTRIC-CANCER;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Nasopharyngeal carcinoma is a prevalent malignant tumor in clinical practice, with the highest incidence rate among otorhinolaryngological malignant tumors. Objectives: This study aims to comprehensively evaluate the clinical efficacy and safety of traditional Chinese medicine compound (CMC) combined with concur-rent radiotherapy and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (LA-NPC). Methods: Relevant essays published before November 20, 2021, were retrieved from China National Knowledge Internet (CNKI), China Science and Technology Journal Database (CQVIP), Wanfang database, PubMed, and Web of Science databases. Randomized controlled trials regarding the clinical efficacy of CMC combined with concur-rent radiotherapy and chemotherapy in the treatment of LA-NPC were included. Results: A total of 15 publications involving 1324 patients were included in this study, including 665 in the experimental group and 659 in the control group. Meta-analyses revealed that compared with radiotherapy or chemotherapy only, CMC combined with con-current radiotherapy and chemotherapy for LA-NPC significantly improved the efficacy [risk ratio (RR)=1.15, 95% confidence interval (95% CI) (1.09, 1.20), P<0.00001], the quality of life [RR=1.35, 95% CI (1.13, 1.62), P=0.0009], immune function indices CD4+ levels [RR=6.2, 95% CI (3.64, 8.76), P<0.00001], CD4+/CD8+ [RR=0.33, 95% CI (0.14, 0.53), P=0.0009], and alleviated the decrease in white blood cell counts [RR=0.67, 95% CI (0.52, 0.86), P=0.002]. Conclusion: CMC combined with concurrent radiotherapy and chemotherapy for the treatment of LA-NPC can significantly improve the efficacy and reduce severe adverse reactions caused by conventional radiotherapy and chemotherapy. However, due to limitations in the quantity and quality of the included studies, more high-quality, multi-center, and large sample-size studies are needed to provide high-level and high-quality medical evidence for systematic evaluation.
引用
收藏
页码:4439 / 4453
页数:15
相关论文
共 50 条
  • [1] Chrono-chemotherapy combined with radiotherapy for locally advanced nasopharyngeal carcinoma: A meta-analysis
    Yang, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1526 - S1526
  • [2] The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis
    Tang, Min
    Jia, Zhongxiong
    Zhang, Ju
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2021, 278 (05) : 1545 - 1558
  • [3] The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis
    Min Tang
    Zhongxiong Jia
    Ju Zhang
    European Archives of Oto-Rhino-Laryngology, 2021, 278 : 1545 - 1558
  • [4] Combined chemotherapy and radiotherapy in the treatment of locally advanced undifferentiated nasopharyngeal carcinoma (LAUNC)
    Barceló, JR
    Muñoz, A
    Rubio, I
    Fernández, R
    Mañé, JM
    Abón, G
    Vivanco, GL
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S64 - S64
  • [5] Efficacy and survival analysis of nimotuzumab combined with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma
    Wang, Lili
    Zhuang, Hengzhao
    Xu, Xiaoyan
    Zhou, Juying
    Jiao, Yang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature
    Langendijk, JA
    Leemans, CR
    Buter, J
    Berkhof, J
    Slotman, BJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4604 - 4612
  • [7] Concurrent chemotherapy with or without nimotuzumab for treatment for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis
    Wang, Bi-Cheng
    Shi, Liang-Liang
    Fu, Chen
    Zhang, Zhan-Jie
    Ba, Li
    Xiong, Ying
    Ding, Qian
    Peng, Gang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (08): : 9998 - 10008
  • [8] A meta-analysis of neoadjuvant chemotherapy plus radiation in the treatment of locally advanced nasopharyngeal carcinoma
    He, Xun
    Xu, Kairui
    Guo, Jiayi
    Zhu, Yalan
    Liang, Xiaomei
    Liu, Lixian
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2015, 11 (06) : C205 - C208
  • [9] Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis
    Tan, Teng Hwee
    Soon, Yu Yang
    Cheo, Timothy
    Ho, Francis
    Wong, Lea Choung
    Tey, Jeremy
    Tham, Ivan W. K.
    RADIOTHERAPY AND ONCOLOGY, 2018, 129 (01) : 10 - 17
  • [10] The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation A meta-analysis
    Fei, Qian
    Chen, Han-Bo
    Zhang, Chun-Mei
    Xu, Jia-Jun
    He, Xia
    Chen, Song-Wang
    MEDICINE, 2021, 100 (14) : E25398